Page 93 - GPD-2-2

Gene & Protein in Disease Verteporfin therapy for triple-negative breast cancer

Author contributions 8. Schütte U, Bisht S, Heukamp LC, et al., 2014, Hippo signaling
mediates proliferation, invasiveness, and metastatic potential
Conceptualization: Sulfath Thottungal Parambil, Lakshmi of clear cell renal cell carcinoma. Transl Oncol, 7(2): 309–321.
Subhadradevi
Data curation: Sulfath Thottungal Parambil https://doi.org/10.1016/j.tranon.2014.02.005
Funding acquisition: Lakshmi Subhadradevi 9. Choi W, Kim J, Park J, et al., 2018, YAP/TAZ initiates gastric
Investigation: Sulfath Thottungal Parambil, Gisha Rose tumorigenesis via upregulation of MYC. Cancer Res, 78(12):
Antony,Ajeesh Babu Littleflower 3306–3320.

Supervision: Lakshmi Subhadradevi https://doi.org/10.1158/0008-5472.CAN-17-3487
Writing – original draft: Sulfath Thottungal Parambil 10. Kim HM, Jung WH, Koo JS, 2015, Expression of Yes-
Writing – reviewing and editing: All authors associated protein (YAP) in metastatic breast cancer. Int J
Clin Exp Pathol, 8(9): 11248–11257.
Ethics approval and consent to participate
11. Yuan M, Tomlinson V, Lara R, et al., 2008, Yes-associated
Not applicable. protein (YAP) functions as a tumor suppressor in breast. Cell
Death Differ, 15(11): 1752–1759.
Consent for publication
https://doi.org/10.1038/cdd.2008.108
Not applicable.
12. Tufail R, Jorda M, Zhao W, et al., 2012, Loss of Yes-
Availability of data associated protein (YAP) expression is associated with
estrogen and progesterone receptors negativity in invasive
The data included in this manuscript will be available from breast carcinomas. Breast Cancer Res Treat, 131: 743–750.
the corresponding author on reasonable request. https://doi.org/10.1007/s10549-011-1435-0

References 13. Wu L, Yang X, 2018, Targeting the Hippo pathway for breast
cancer therapy. Cancers (Basel), 10(11): 422.
1. Perou CM, Sørlie T, Eisen MB, et al., 2000, Molecular portraits
of human breast tumours. Nature, 406(6797): 747–752. https://doi.org/10.3390/cancers10110422
https://doi.org/10.1038/35021093 14. Wang Z, Kong Q, Su P, et al., 2020, Regulation of Hippo
signaling and triple negative breast cancer progression by an
2. Maqbool M, Bekele F, Fekadu G, 2022, Treatment strategies ubiquitin ligase RNF187. Oncogenesis, 9(3): 36.
against triple-negative breast cancer: An updated review.
Breast Cancer (Dove Med Press), 14: 15–24. https://doi.org/10.1038/s41389-020-0220-5
15. Schmidt-Erfurth U, Hasan T, 2000, Mechanisms of action
https://doi.org/10.2147/BCTT.S348060
of photodynamic therapy with verteporfin for the treatment
3. Yin L, Duan JJ, Bian XW, et al., 2020, Triple-negative breast of age-related macular degeneration. Surv Ophthalmol,
cancer molecular subtyping and treatment progress. Breast 45(3): 195–214.
Cancer Res, 22: 61.
https://doi.org/10.1016/S0039-6257(00)00158-2
https://doi.org/10.1186/s13058-020-01296-5
16. Richter A, Sternberg E, Waterfield E, et al., 1989,
4. Chang-Qing Y, Jie L, Shi-Qi Z, et al., 2020, Recent treatment Characterization of Benzoporphyrin Derivative, A New
progress of triple negative breast cancer. Prog Biophys Mol Photosensitizer. In: Proceedings of the Society of Photo-
Biol, 151: 40–53. Optical Instrumentation Engineers (SPIE), Advances in
https://doi.org/10.1016/j.pbiomolbio.2019.11.007 Photochemotherapy. Vol. 997. p132-138.
5. Edgar BA, 2006, From cell structure to transcription: Hippo https://doi.org/10.1117/12.960196
forges a new path. Cell, 124(2): 267–273. 17. Fingar VH, Kik PK, Haydon PS, et al., 1999, Analysis of
acute vascular damage after photodynamic therapy using
https://doi.org/10.1016/j.cell.2006.01.005
benzoporphyrin derivative (BPD). Br J Cancer, 79(11):
6. Saucedo LJ, Edgar BA, 2007, Filling out the Hippo pathway. 1702–1708.
Nat Rev Mol Cell Biol, 8(8): 613–621.
https://doi.org/10.1038/sj.bjc.6690271
https://doi.org/10.1038/nrm2221
18. Liu-Chittenden Y, Huang B, Shim JS, et al., 2012, Genetic
7. Poma AM, Torregrossa L, Bruno R, et al., 2018, Hippo and pharmacological disruption of the TEAD-YAP complex
pathway affects survival of cancer patients: Extensive analysis suppresses the oncogenic activity of YAP. Genes Dev, 26(12):
of TCGA data and review of literature. Sci Rep, 8(1): 10623. 1300–1305.
https://doi.org/10.1038/s41598-018-28928-3 https://doi.org/10.1101/gad.192856.112

Volume 2 Issue 2 (2023) 10 https://doi.org/10.36922/gpd.0658